As previously reported, Needham downgraded Rocket Pharmaceuticals (RCKT) to Hold from Buy and removed the firm’s prior $42 price target on shares after Rocket reported a patient death in its registrational study for RP-A501 in Danon disease. The FDA has placed the study on clinical hold and it remains unclear when/if dosing will resume, notes the analyst. While the firm continues to have a favorable view of RP-A501’s efficacy it sees increased uncertainty for the product, which it calls the company’s “main value driver.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals downgraded to Hold from Buy at Needham
- Resilience and Proactive Measures: Rocket Pharmaceuticals’ Path to Overcoming Clinical Challenges and Future Success
- Rocket’s Danon update raises specter of worst-case scenario, Leerink says
- Rocket Pharmaceuticals price target lowered to $16 from $32 at Wedbush
- Rocket Pharmaceuticals Stock (RCKT) Plummets 57% on FDA Intervention